NCT01586442View on ClinicalTrials.gov

Comparison of Eplerenone Versus Spironolactone in Heart Failure Patients With Glucose Intolerance or Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

March 31, 2015

Study Completion Date

July 29, 2018

Conditions
Heart FailureType 2 DiabetesGlucose Intolerance
Interventions
DRUG

Eplerenone

Eplerenone 25mg once daily titrated to 50 mg once daily for 4 months

DRUG

Spironolactone

Spironolactone 12,5mg daily titrated to 25mg once daily for 16 weeks

Trial Locations (1)

H1T 1C8

Montreal Heart Institute, Montreal

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Montreal Heart Institute

OTHER

NCT01586442 - Comparison of Eplerenone Versus Spironolactone in Heart Failure Patients With Glucose Intolerance or Type 2 Diabetes | Biotech Hunter | Biotech Hunter